Protocol Ledger

NCT06435182 · Phase II · COMPLETED

Study of OT202 in Treating Moderate to Severe Dry Eye

Interventional Phase II clinical trial protocol NCT06435182 sponsored by Ocumension Therapeutics (Shanghai) Co in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-04-10 Enrollment: 213 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06435182
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)213 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06435182
Protocol FieldVerified Registry Value
NCT IdentifierNCT06435182
Consolidated Lead SponsorOcumension Therapeutics (Shanghai) Co
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment213 participants (ACTUAL)
Registered Start Date2023-04-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI